- Osteoporosis and fracture are a growing problem in the male population. Weekly doses of alendronic acid are not licensed in this group for either treatment or prophylaxis of bone loss.
- Several randomised controlled trials have indicated that alendronic acid is effective in increasing bone mineral density in men when administered in weekly doses of 70mg, and can help prevent bone loss associated with androgen deprivation therapy.
- Due to the very strict and inconvenient administration requirements for alendronic acid, reducing administration frequency may improve compliance.
Senior Medicines Information Pharmacist , Regional Drug and Therapeutics Centre